Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CollaGenex Pharmaceuticals has initiated a Phase II, double-blinded, placebo- and active-controlled, dose-finding clinical trial to evaluate the safety and efficacy of its novel compound, becocalcidiol, for the treatment of psoriasis.
Subscribe to our email newsletter
The study will enroll 300 patients with mild to moderate psoriasis at 20 investigational centers across the US. The placebo- and active-controlled study will evaluate three concentrations of becocalcidiol administered once daily versus a vehicle and active control over a 12-week period.
Klaus Theobald, chief medical officer of CollaGenex, said: “We are encouraged by the results from an earlier Phase II trial that demonstrated a dose-response relationship for becocalcidiol in the treatment of psoriasis. The current trial is designed to further explore and optimize the treatment regimen.”